| Website | pharnext.com |
| Category | BioTech |
| Phone | 33 1 55 42 62 00 |
| Employees | |
| Founded | 2007 |
| TOTAL | $19.9M |
| FUNDING TOTAL | $19.9M |
| Series A, 6/10 Truffle Capital Aurinvest | $5.8M |
| Series B, 9/11 Truffle Capital | €2.5M |
| Venture Round, 2/12 Parinvest Truffle Capital | €8M |
Pharnext SAS, a biopharmaceutical company, engages in the development of treatments for severe neurological diseases. The company specializes in drug repositioning. Its target pathologies include Charcot-Marie-Tooth disease; and diabetic and toxic peripheral neuropathies, as well as severe neurodegenerative diseases in general and peripheral neuropathies. The company was founded in 2007 and is based in Paris, France.
